Lessons From ASCO 2026

• by Karan Arora

• September 21, 2026

Mild metabolic profile may mask MASLD risk

Five reproducible MASLD subtypes showed distinct genetic profiles and patterns of metabolic comorbidity and disease progression.

• by Andrea Surnit

• September 10, 2026

• 4 min

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

• by Kathryn Wighton

• September 21, 2026

• 2 min

Clonal Candida auris candidemia outbreak in a tertiary care center with the first echinocandin-resistant isolates reported in Türkiye

• by Bram Spruijtenburg, Nevzat Unal, Carolina Melchior do Prado, Jacques F. Meis, Oğuzhan Bingöl, Tolga Toyran, Nida Akar, Nurettin Ay, Tuğba Arslan-Gülen, Tuba Turunç, Koray Daş, Ümit Çelik, Merve Kılıç-Çil, Macit Ilkit, Eelco F.J. Meijer

• September 9, 2026